Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
China Medical Univ. xanthine oxidase compound 9m
- Development stage
- Unknown
- Lead developer
- China Medical University
01
Overview
China Medical Univ. xanthine oxidase compound 9m: sourced facts only. name: "Among these compounds, 9m emerged as the most effective XO inhibitor with an IC50 value of 0.70 μM, which was approximately 14-fold more potent than allopurinol." [PMID:35077850]; target: "Among these compounds, 9m emerged as the most effective XO inhibitor with an IC50 value of 0.70 μM, which was approximately 14-fold more potent than allopurinol." [PMID:35077850]; developer: "School of Pharmacy, China Medical University, 77 Puhe Road, North New Area, Shenyang 110122, China." [PMID:35077850]
Beyond the preview
Go deeper on China Medical Univ. xanthine oxidase compound 9m.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on China Medical Univ. xanthine oxidase compound 9m.